Expression of monocyte subsets and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis

Jaipersad, Anthony; Shantsila, Alena; Lip, Gregory Y. H.; Shantsila, Eduard

doi:10.3109/07853890.2014.931101

Cited by 34 publications

(29 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, previous data suggests that the intermediate subset secretes increased amounts of TNF-α in patients with CAD and therefore can exert proinflammatory functions5. Previous reports indicate that classical CD14 ++ CD16 − monocytes, however, can predict cardiovascular events in a randomly selected subject population within the Malmö Diet and Cancer Study8 and associate with subclinical systemic atherosclerosis and increased carotid intima-media thickness18. In addition, patient risk factors may affect monocyte subset populations.…”

Section: Discussionmentioning

confidence: 99%

The “Intermediate” CD14++CD16+ monocyte subset increases in severe peripheral artery disease in humans

Wildgruber

Aschenbrenner

Wendorff

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Monocytes are key players in atherosclerotic. Human monocytes display a considerable heterogeneity and at least three subsets can be distinguished. While the role of monocyte subset heterogeneity has already been well investigated in coronary artery disease (CAD), the knowledge about monocytes and their heterogeneity in peripheral artery occlusive disease (PAOD) still is limited. Therefore, we aimed to investigate monocyte subset heterogeneity in patients with PAOD. Peripheral blood was obtained from 143 patients suffering from PAOD (Rutherford stage I to VI) and three monocyte subsets were identified by flow cytometry: CD14++CD16− classical monocytes, CD14+CD16++ non-classical monocytes and CD14++CD16+ intermediate monocytes. Additionally the expression of distinct surface markers (CD106, CD162 and myeloperoxidase MPO) was analyzed. Proportions of CD14++CD16+ intermediate monocyte levels were significantly increased in advanced stages of PAOD, while classical and non-classical monocytes displayed no such trend. Moreover, CD162 and MPO expression increased significantly in intermediate monocyte subsets in advanced disease stages. Likewise, increased CD162 and MPO expression was noted in CD14++CD16− classical monocytes. These data suggest substantial dynamics in monocyte subset distributions and phenotypes in different stages of PAOD, which can either serve as biomarkers or as potential therapeutic targets to decrease the inflammatory burden in advanced stages of atherosclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

The “Intermediate” CD14++CD16+ monocyte subset increases in severe peripheral artery disease in humans

Wildgruber

Aschenbrenner

Wendorff

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Of five different measurements over time in this study, CD14 ++ CD16 + classical monocytes were most consistently (four out of five) associated with recurrent CVD events (100). In addition, the classical CD14 ++ CD16 + monocyte was significantly associated with carotid atherosclerosis and intraplaque neovascularization (104). In two other studies, the total monocyte count did not independently prognosticate mortality (74, 83).…”

Section: Monocytesmentioning

confidence: 99%

Prognostic Value of Circulating Inflammatory Cells in Patients with Stable and Acute Coronary Artery Disease

Meeuwsen

Wesseling

Hoefer

et al. 2017

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Atherosclerosis is a lipid driven chronic inflammatory disease underlying the majority of ischemic events such as myocardial infarction or stroke. Clinical management of ischemic events has improved considerably in the past decades. Accordingly, survival rates have increased. Nevertheless, 12% of patients die within 6 months after the initial event. To improve secondary prevention, appropriate risk prediction is key. However, up to date, there is no clinically available routine marker to identify patients at high risk for recurrent cardiovascular events. Due to the central role of inflammation in atherosclerotic lesion progression and destabilization, many studies have focused on the role of circulating inflammatory cells in these processes. This review summarizes the current evidence on the potential of circulating inflammatory cells as biomarkers for recurrent adverse manifestations in acute coronary syndrome and stable coronary artery disease patients.

show abstract

“…Vulnerable coronary plaques are closely related to ACS, and carotid atherosclerostic plaques have a similar pathologic basis as coronary plaques. Neovascularization in plaques was identified after studies concerning its major characteristic of plaque instability and its status as an independent predictor of ACS, eventually resulting in plaque rupture and hemorrhage, with a close correlation with the occurrence of clinical cardiovascular events . Detecting the correlation between the degree of plaque enhancement and the density of neovascularization in plaques by contrast‐enhanced US can provide rating information for the risk of carotid plaques.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Carotid Plaque Neovascularization in Patients With Coronary Heart Disease on Contrast‐Enhanced Ultrasonography

Qin

Zhang

Wang

et al. 2017

J of Ultrasound Medicine

View full text Add to dashboard Cite

show abstract

Expression of monocyte subsets and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis

Abstract: In this pilot study classical monocytes (Mon1) represent the only monocyte subset predictive of the severity of carotid and systemic atherosclerosis, such as carotid intima-media thickness, degree of carotid stenosis, and presence of carotid intraplaque neovascularization.

Cited by 34 publications

References 44 publications

The “Intermediate” CD14++CD16+ monocyte subset increases in severe peripheral artery disease in humans

The “Intermediate” CD14++CD16+ monocyte subset increases in severe peripheral artery disease in humans

Prognostic Value of Circulating Inflammatory Cells in Patients with Stable and Acute Coronary Artery Disease

Evaluation of Carotid Plaque Neovascularization in Patients With Coronary Heart Disease on Contrast‐Enhanced Ultrasonography

Contact Info

Product

Resources

About